
Sep 30, 2026 · 59 min
Strata bets on logistics as transplant technology fragments
Strata Critical Medical (SRTA): The Organ Transplant Logistics Roll-Up
Strata’s growth depends on whether its integrated logistics and clinical platform can capture expanding transplant pathways without taking on excessive asset or acquisition risk.
- 1Strata combines time-sensitive transport, organ recovery, and clinical services while remaining device-agnostic across evolving transplant technologies.
- 2Management sees mid- to high-single-digit organic growth, with additional upside from DCD donation, perfusion, recovery, and services per donor.
- 3Disciplined acquisitions and selective aircraft ownership support scale, but long-term value depends on free cash flow and operating performance.
Don't miss
Will Heyburn explains why Strata’s aircraft ownership is a strategic capability for selected opportunities, not a core requirement for growth.
The brief
Strata Critical operates where transplant medicine meets time-sensitive infrastructure, coordinating air and ground logistics, organ recovery, and clinical services across the U.S. ecosystem.
Will Heyburn and Mat Schneider describe a device-agnostic platform designed to serve transplant centers as technologies, donation pathways, and competitive structures evolve.
The company owns only about 30% of its aircraft, treating ownership as strategic leverage for selected contracts rather than a prerequisite for scaling.
Management sees baseline organic growth in the mid- to high-single digits, with further potential from DCD donors, perfusion, third-party recovery, and more services per donor.
The larger thesis is that fragmented future pathways—including new devices and potential xenotransplants—could make Strata’s logistics and clinical platform more valuable over time.
What was said on this episode
38 statements · 32 positive · 1 negative · 5 neutral
- Will Heyburnon Strata Critical clinical businessPositive4:29
Strata’s clinical business grew over 20% quarter over quarter and the company is EBITDA and free-cash-flow positive
“We're growing very quickly. The clinical part of our business grew nearly 20%, more than 20% quarter over quarter in the most recent quarter. We're adjusted EBITDA and free cash flow positive”
Listen at 4:29
- Will Heyburnon Strata Critical clinical businessPositive4:31
Strata’s clinical business grew more than 20% quarter over quarter recently.
“The clinical part of our business grew nearly 20%, more than 20% quarter over quarter in the most recent quarter.”
Listen at 4:31
- Will Heyburnon Strata CriticalPositive4:38
Strata is adjusted EBITDA and free-cash-flow positive.
“We're adjusted EBITDA and free cash flow positive”
Listen at 4:38
- Will Heyburnon Strata Critical acquisition strategyPositive4:41
Strata plans acquisitions to expand its national footprint alongside organic growth.
“we're executing incrementally to this strong organic growth on a plan of acquisitions to continue to build our national footprint”
Listen at 4:41
- Will Heyburnon Strata Critical organ-transplant servicesPositive5:57
Strata’s integrated services can solve the organ supply problem
“This is entirely a supply problem, and in our view, it's a supply problem that can be solved by putting the pieces of the puzzle together that we provide at Strata.”
Listen at 5:57
- Will Heyburnon Strata CriticalPositive7:59
Strata believes it is unique in the transplant-services industry.
“we really believe we're one of a kind in this industry”
Listen at 7:59
- Will Heyburnon Normothermic regional perfusionPositive8:41
Normothermic regional perfusion can repair donor-organ damage at lower cost
“we're able to pump oxygenated blood through all the organs inside the donor to repair damage that may be done during the dying process at a much lower cost.”
Listen at 8:41
- Will Heyburnon Strata’s organ-transport modelPositive10:06
Strata can delay aircraft activation until organs are accepted for transplant
“we don't need to turn on an airplane until we know that those organs are going to be accepted for transplant.”
Listen at 10:06
- Will Heyburnon Strata Critical delayed aircraft activationPositive10:21
Delaying aircraft activation until organ acceptance can reduce transplant logistics costs.
“we can save a lot of money for transplant centers and for the system if we wait to turn on expensive airplanes until we know that those organs are going to be utilized.”
Listen at 10:21
- Will Heyburnon Normothermic regional perfusionPositive11:43
Normothermic perfusion produces 50% more usable organs per donor on average
“resulting in, on average, 50% more usable organs per organ donor.”
Listen at 11:43
- Will Heyburnon Donation after circulatory deathPositive12:05
Donation after circulatory death has grown around 20% annually in recent years.
“has been growing consistently in the 20% range over the last several years.”
Listen at 12:05
- Will Heyburnon Continuous distribution organ allocationPositive12:49
Organ allocation is planned to shift toward continuous distribution prioritizing patient sickness.
“The plan is to move to what's called continuous distribution, a national allocation methodology that focuses primarily on the sickness of the patient”
Listen at 12:49
- Will Heyburnon Continuous distribution for lung allocationNeutral13:01
Continuous distribution increased lung donor-recipient distance by nearly 80%
“When we saw lungs move from acuity circles to continuous distribution, we saw a nearly 80% increase in the distance between donors and recipients.”
Listen at 13:01
- Will Heyburnon Strata Critical transplant logistics businessPositive13:54
Strata will benefit from faster-growing transplant segments and longer transport trips
“Our business model is more exposed to those faster-growing parts of the transplant industry and will benefit from those longer trips that we talked about”
Listen at 13:54
- Will Heyburnon Strata Critical acquisitionsPositive14:51
Strata has acquired four smaller regional players year to date.
“we've made 4 year to date of smaller regional players”
Listen at 14:51
- Will Heyburnon Donor-recipient organ travel distancePositive15:07
Donor-recipient travel distances have increased about 68%.
“we've already seen about a 68% increase as these regulations have continued to evolve and as perfusion technology has allowed us to extend the distance that we can travel with these donor organs.”
Listen at 15:07
- Will Heyburnon Strata Critical acquisition capacityPositive17:08
Strata is well capitalized and positioned to acquire quality regional providers.
“we're very well capitalized and we're very well positioned to find attractive, quality regional providers”
Listen at 17:08
- Will Heyburnon Strata Critical acquisition strategyPositive17:39
Strata targets acquisitions at mid-single-digit adjusted EBITDA multiples
“We're focused on being disciplined with our capital outlay, mid-single-digit adjusted EBITDA acquisition multiples for all of the acquisitions that we've completed to date and for everything that's in our pipeline today.”
Listen at 17:39
- Will Heyburnon Strata Critical acquisitionsPositive17:43
Strata’s completed and pipeline acquisitions carry mid-single-digit EBITDA multiples.
“mid-single-digit adjusted EBITDA acquisition multiples for all of the acquisitions that we've completed to date and for everything that's in our pipeline today.”
Listen at 17:43
- Will Heyburnon Strata CriticalPositive19:33
Strata continues to grow attractively, especially in clinical services.
“The company continues to grow attractively, particularly in our clinical business.”
Listen at 19:33
- Will Heyburnon Strata Critical transplant clinical businessPositive19:38
Strata’s transplant clinical business grew 22% organically and 27% including acquisitions quarter over quarter.
“You see 22% organic quarter-over-quarter growth, 27% when you include the benefit of our acquisitions on that transplant clinical business.”
Listen at 19:38
- Will Heyburnon Strata Critical business mixPositive20:11
Strata’s clinical mix shift is increasing blended gross and EBITDA margins
“you've seen that consistent growth in our overall blended gross margins as well as our blended adjusted EBITDA margins as we continue to shift our mix towards that clinical business.”
Listen at 20:11
- Will Heyburnon US transplant-services platformsNeutral22:53
The US may ultimately support only one or two transplant-services platforms
“I think it could be true that there's only place for one or two services platforms across the United States that are supporting all these things.”
Listen at 22:53
- Will Heyburnon Device-agnostic transplant servicesPositive25:39
Device-agnostic transplant services should generate stronger economies of scale
“we do believe that the economies of scale are going to make more sense if you approach the services side of things without a captive mindset.”
Listen at 25:39
- Will Heyburnon Strata’s organ-recovery modelPositive28:13
Strata’s low-cost recovery model enables attempts on marginal donors
“We unlock the hope that a donor that looks like it's not going to produce viable organs might”
Listen at 28:13
- Will Heyburnon Clinical transplant services competitionNeutral30:39
Clinical-services competition depends more on results and reputation than price
“on the clinical side of things, it's much more about results and reputation.”
Listen at 30:39
- Will Heyburnon Strata aircraft networkPositive32:28
Strata’s aircraft network provides a major competitive advantage
“provides us a huge competitive advantage.”
Listen at 32:28
- Will Heyburnon Strata owned aircraft fleetNeutral35:07
Strata’s owned-aircraft fleet does not need to scale with business growth
“It's not something that needs to scale with our business.”
Listen at 35:07
- Will Heyburnon Helicopter organ transportPositive36:50
Helicopter transport can cost one-third as much as a jet and be faster
“It's going to be a third of the cost of a jet, but let's save you some money. It's actually going to be faster because we're going to fly direct”
Listen at 36:50
- Will Heyburnon Organ-transport technologyPositive37:50
Transport technology could expand viable organ-transport distances and improve short-trip efficiency
“technology over the next decade or so could really open up the aperture farther and then create some efficiencies on the short end.”
Listen at 37:50
- Mat Schneideron Strata Critical organic revenuePositive39:06
Strata’s base case is mid-to-high single-digit organic revenue growth
“Our base case is a mid to high single-digit organic revenue growth”
Listen at 39:06
- Mat Schneideron Normothermic regional perfusionPositive39:43
NRP is moving toward becoming a standard of care
“We believe that it's moving towards a standard of care over time.”
Listen at 39:43
- Mat Schneideron Normothermic regional perfusion adoptionPositive42:35
NRP adoption could reach 70% to above 80% of DCD cases
“We believe NRP is moving towards a standard of care. We believe that's something in the 70, 80-plus range.”
Listen at 42:35
- Will Heyburnon New DCD rulesPositive45:22
New DCD rules will increase donor authorization without structurally hindering procurement
“we're really hopeful that the primary outcome of these rules is not going to be to create any structural difficulty in procuring organs, but will actually result in more donors being authorized.”
Listen at 45:22
- Mat Schneideron Strata third-party organ recoveryNeutral46:48
Strata’s share of outsourced third-party recovery is below 10%
“we think our share is less than 10% overall for third-party recovery”
Listen at 46:48
- Will Heyburnon Strata acquisition processNegative50:30
Strata abandons acquisitions that fail internal return thresholds
“we do walk when things don't meet those return thresholds.”
Listen at 50:30
- Will Heyburnon Organ-donation pathwaysPositive57:12
New organ-donation pathways will emerge over the next five years
“I think if you look 5 years from now, there are going to be some pathways that we see the beginning of right now to saving lives through organ donation”
Listen at 57:12
- Will Heyburnon Strata Critical transplant platformPositive57:42
Strata aims to become an end-to-end platform connecting emerging transplant technologies
“we hope that we are the connective tissue, that open-source, end-to-end platform that makes all these great new ideas and inventions work and get to where they need to go on time”
Listen at 57:42
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.